What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167.

Abstract

The HER2 gene and its role in pathogenicity in human breast cancer were detected in the 1980s. Trastuzumab is a monoclonal antibody directed against the HER2 membrane receptor. The aim of this article is to describe chemotherapy-trastuzumab combinations that have been evaluated in patients with HER2-positive metastatic breast cancer, and to define the possible standards and options.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Neoplasm Metastasis
  • Randomized Controlled Trials as Topic / methods
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab